How Much Do GLP-1 Drugs Cost? A Complete Breakdown
GLP-1 Access and Cost
$1,349/month
Wegovy's list price is $1,349 per month without insurance, making it the most expensive branded GLP-1 for weight management. TrumpRx negotiated pricing brings injectable GLP-1s to $349/month.
GoodRx pricing data, March 2026
GoodRx pricing data, March 2026
View as imageGLP-1 receptor agonists produce 15-22% body weight loss in clinical trials. Semaglutide 2.4 mg (Wegovy) produced 14.9% weight loss in the STEP 1 trial.[1] Tirzepatide (Zepbound) produced up to 22.5% weight loss in SURMOUNT-1.[2] Those numbers explain the demand. The prices explain why most people who could benefit from these drugs cannot access them. This article breaks down what every GLP-1 actually costs in 2026, from brand-name list prices to compounded alternatives to the new government-negotiated pricing programs. For the economic argument for and against covering these drugs, see our pillar article on cost-effectiveness of GLP-1s.
Key Takeaways
- Wegovy (semaglutide for weight) lists at $1,349/month; Ozempic (semaglutide for diabetes) lists at $935/month for the same molecule at different doses (GoodRx, March 2026)
- Mounjaro and Zepbound (tirzepatide) list at $1,023-$1,086/month depending on dose and indication
- TrumpRx direct-to-consumer pricing brings injectable GLP-1s to $299-$449/month for Zepbound and $349/month for Wegovy/Ozempic
- Compounded semaglutide costs $149-$299/month but faces restricted availability after the FDA ended the semaglutide shortage in February 2026
- Medicare Part D will cover GLP-1s starting mid-2026 with approximately $50/month copays after deductibles
- Without insurance or discount programs, a year of brand-name GLP-1 therapy costs $11,220 to $16,188
Brand-name GLP-1 list prices in 2026
List price (also called wholesale acquisition cost) is what the manufacturer charges before any discounts, rebates, or insurance negotiations. Almost nobody pays list price, but it sets the baseline from which all other prices are negotiated.
Semaglutide (Novo Nordisk)
- Ozempic (diabetes indication): approximately $935/month
- Wegovy (weight management indication): approximately $1,349/month
- Rybelsus (oral semaglutide for diabetes): approximately $936/month
Tirzepatide (Eli Lilly)
- Mounjaro (diabetes indication): approximately $1,023/month
- Zepbound (weight management indication): approximately $1,023-$1,086/month depending on dose
Liraglutide (Novo Nordisk)
- Victoza (diabetes, 1.8 mg): approximately $989/month
- Saxenda (weight management, 3.0 mg): approximately $1,349/month
Dulaglutide (Eli Lilly)
- Trulicity (diabetes): approximately $970/month
Exenatide (AstraZeneca)
- Bydureon BCise (diabetes): approximately $775/month
The weight management versions (Wegovy, Zepbound, Saxenda) consistently cost more than the diabetes versions of the same or similar molecules, reflecting different pricing strategies for different insurance coverage landscapes. For a full comparison of how these drugs differ pharmacologically, see our article on every GLP-1 receptor agonist compared.
What you actually pay with commercial insurance
Most people with employer-sponsored or marketplace health insurance do not pay list price. Actual out-of-pocket costs depend on three variables: whether the drug is on the plan's formulary, what tier it occupies, and what prior authorization requirements apply.
Preferred formulary position: If the plan covers a specific GLP-1 as a preferred brand, copays typically range from $25-$75/month after meeting the deductible.
Non-preferred or specialty tier: Many plans place GLP-1s on specialty tiers with coinsurance (percentage-based cost sharing) rather than flat copays. At 25-33% coinsurance on a $1,000+ drug, out-of-pocket costs reach $250-$350/month.
Prior authorization: Nearly all commercial plans require prior authorization for GLP-1s, particularly for weight management indications. Common requirements include documented BMI above 30 (or above 27 with comorbidities), failed attempts at diet and exercise, and sometimes failure of other weight loss medications first. For the full picture of why GLP-1 insurance approval is so difficult, see our dedicated article.
Step therapy: Some plans require trying cheaper alternatives (metformin, sulfonylureas for diabetes; orlistat for weight) before approving GLP-1s.
The practical result: even with insurance, many patients face $100-$350/month out-of-pocket for GLP-1 therapy after navigating prior authorization.
TrumpRx and government-negotiated pricing
In 2026, the TrumpRx program negotiated direct-to-consumer GLP-1 pricing that bypasses traditional insurance channels:
- Zepbound: $299-$449/month depending on dose
- Ozempic and Wegovy: $349/month for injectable maintenance dosing
- Lowest starting dose: $149/month
These prices represent a 60-75% reduction from list price. The program works through direct manufacturer agreements rather than insurance, meaning patients pay these prices out of pocket regardless of insurance status.
The limitation: these prices are available only through the TrumpRx platform and participating pharmacies. Patients with insurance cannot currently apply these prices to their insurance plans' out-of-pocket maximums or deductibles.
Medicare Part D coverage (starting mid-2026)
The Inflation Reduction Act and subsequent policy changes expanded Medicare coverage of GLP-1s for both diabetes and weight management. Key details:
- Monthly copay approximately $50 after deductibles
- Federal government pays approximately $245/month to manufacturers
- Applies to injectable Mounjaro, Ozempic, Wegovy, and Zepbound
- State Medicaid programs can access the same negotiated price
- Coverage expected to begin mid-2026
This represents a transformative change for Medicare beneficiaries, who previously had to pay full cash price for weight-management GLP-1s. An estimated 3.4 million Medicare enrollees may become eligible for GLP-1 coverage under these new rules.
Compounded semaglutide: the gray market
Compounded semaglutide emerged as a lower-cost alternative during the FDA-declared semaglutide shortage (2022-2025). Compounding pharmacies produced their own semaglutide formulations at prices of $149-$299/month, roughly 80% less than brand-name Wegovy.
The February 2026 regulatory shift: When the FDA ended the semaglutide shortage, it tightened compounding rules. Pharmacies can now compound semaglutide only for patients with documented medical needs such as allergies to brand-name excipients or requirements for non-standard doses. General weight management prescriptions no longer qualify.
Price impact: Reduced availability has pushed compounded semaglutide prices up at many telehealth providers. Some now charge $200-$399/month, narrowing the gap with TrumpRx pricing.
Quality considerations: Compounded medications are not FDA-approved as finished products. They have not been evaluated for safety, effectiveness, or quality in the same way as brand-name drugs. For a detailed comparison, see our article on compounded semaglutide vs brand Wegovy.
The annual cost calculation
For someone considering long-term GLP-1 therapy (these drugs are prescribed indefinitely; weight typically returns after discontinuation), annual costs vary dramatically:
| Option | Monthly | Annual |
|---|---|---|
| Wegovy list price | $1,349 | $16,188 |
| Ozempic list price | $935 | $11,220 |
| Preferred insurance copay | $25-75 | $300-900 |
| Non-preferred insurance | $250-350 | $3,000-4,200 |
| TrumpRx Zepbound | $299-449 | $3,588-5,388 |
| TrumpRx Wegovy | $349 | $4,188 |
| Medicare Part D | ~$50 | ~$600 |
| Compounded semaglutide | $149-299 | $1,788-3,588 |
These figures do not include the cost of required medical visits, lab monitoring, or the economic value of weight-related health improvements.
Why GLP-1s cost what they do
Three factors drive GLP-1 pricing:
R&D and trial costs. The semaglutide clinical program (STEP, SUSTAIN, PIONEER trials) enrolled over 25,000 subjects across more than a dozen phase 3 trials. The tirzepatide program (SURMOUNT, SURPASS) was comparably large.[1][2] Recovering these development costs drives initial pricing. SURMOUNT-2 alone enrolled over 900 patients across 71 sites in seven countries.[3]
Manufacturing complexity. GLP-1 agonists are peptide drugs produced through recombinant DNA technology or chemical synthesis, not small-molecule chemistry. Manufacturing at scale requires specialized biopharmaceutical facilities.
Demand exceeding supply. The semaglutide shortage that persisted from 2022 to early 2026 reflected manufacturing capacity failing to keep pace with explosive demand. When demand exceeds supply, pricing power increases. For the full story of the GLP-1 shortage, see our sibling article.
What telehealth and online clinics charge
The rise of GLP-1 telehealth prescribing has created a parallel market with its own pricing structure. Online clinics typically bundle the medication, consultations, and monitoring into monthly subscription programs:
- Compounded semaglutide programs: $149-$399/month (medication + visits)
- Brand-name prescribing programs: $50-$150/month for the prescribing service, plus pharmacy costs for the medication
- All-inclusive brand programs: $500-$800/month (medication + unlimited consultations + lab work)
These programs are cash-pay and typically do not file insurance claims. The convenience and reduced prior authorization friction make them attractive despite higher total cost compared to well-insured patients.
The Bottom Line
GLP-1 drug costs in 2026 range from approximately $50/month (Medicare Part D copay) to $1,349/month (Wegovy list price), with multiple pricing tiers in between. TrumpRx government-negotiated pricing ($149-$449/month) and compounded semaglutide ($149-$299/month, now restricted) have created new access points below traditional insurance pricing. Medicare Part D coverage starting mid-2026 will be the largest single expansion of GLP-1 access, potentially reaching 3.4 million beneficiaries. The gap between what these drugs cost and what most patients can afford remains the central barrier to the public health impact that their clinical trial results suggest is possible.